Daily Low-Dose Ketamine: Does It Work for Depression?

What Is Low-Dose Ketamine Therapy?

Low-dose ketamine therapy involves using sub-anesthetic amounts of the medication prescribed by a licensed provider to treat mental health conditions. Ketamine has been an FDA-approved anesthetic since 1970 and has been on the WHO List of Essential Medicines since 1985.³ Prescribing it for depression is off-label, which is a widespread and legally accepted practice in psychiatry.⁴

What Is the Difference Between Microdose, Low-Dose, and Therapeutic-Dose Ketamine?

In commercial use, "microdose," "low-dose," and "sub-perceptual" often refer to the same thing: a dose small enough that the patient experiences little to no dissociation or perceptual changes during administration. In practice, these protocols are taken at home as part of a daily routine, similar to other prescribed medications. There is no structured treatment session built around the dose; the patient takes it and continues their day.

Therapeutic-dose ketamine is a different category. Therapeutic doses are large enough to produce perceptual changes (dissociation, altered perception of time and self), and those perceptual changes are considered part of the treatment mechanism. Therapeutic doses are individually titrated by a licensed provider based on patient response, treatment history, and clinical assessment, not fixed across patients. Treatments are structured around dedicated sessions on a periodic schedule, typically with preparation beforehand, the dosing experience within a defined treatment window, and a settling period afterward before returning to normal activities.

The distinction matters for evaluating research: studies using sub-perceptual doses on daily schedules are testing a fundamentally different intervention than studies using therapeutic doses on periodic schedules. Findings from one category do not generalize to the other.

• Sub-perceptual or microdose ketamine: typically around 10-30 mg, often intended to minimize dissociative or perceptual effects, used in commercial daily protocols.
• Therapeutic-dose ketamine: individually titrated by a clinician, perceptual changes expected as part of the mechanism, used in periodic dosing protocols.

What Is the Difference Between Esketamine and Ketamine?

Racemic ketamine is a 50:50 mixture of S-enantiomers and R-enantiomers. Esketamine is the S-enantiomer alone, possessing approximately three to four times higher NMDA receptor affinity than R-ketamine.

The only FDA-approved ketamine product for depression is intranasal esketamine (Spravato). The FDA approved it for treatment-resistant depression and, subsequently, for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, requiring administration under REMS guidelines in certified healthcare settings.⁵

Most commercial at-home ketamine therapy providers prescribe racemic ketamine rather than esketamine.

What Does the Research Say About Daily Low-Dose Ketamine?

The truth is that no published clinical trial has tested the once-daily oral racemic ketamine protocol that commercial daily-dosing providers prescribe for depression. Two studies come close, but each diverges from the commercial protocol on a critical dimension. The closer match by drug used a thrice-weekly schedule, not daily. The closer match by schedule used a different drug (esketamine instead of racemic ketamine), and administered it three times per day rather than once. The full protocols are below.

Study 1: Smith-Apeldoorn 2022¹

• Drug: Oral esketamine (not racemic ketamine)
• Schedule: Three times daily for 21 days
• Total daily dose: Titrated to 1.25 mg/kg
• Sample: n=7
• Results: 0/7 response, 0/7 remission, 16.5% HRSD reduction
• Authors' conclusion: "Therapeutic effects were modest"

Study 2: Domany 2019⁶

• Drug: Oral racemic ketamine (matches commercial drug)
• Schedule: Thrice-weekly for 21 days (not daily)
• Dose: 1 mg/kg
• Sample: RCT, n=41
• Results: 31.8% response, 27.3% remission

No other prospective clinical trial has tested an oral ketamine protocol at this dose range and frequency. The same research team behind the Smith-Apeldoorn pilot did publish a larger follow-up study several years later, with a different schedule.²

What Did Follow-Up Research on Oral Ketamine Find?

In 2025, the research group behind the 2022 pilot published a larger follow-up trial. The researchers used the same drug (oral esketamine) but employed a twice-weekly schedule rather than three-times-daily dosing.²

This follow-up enrolled 185 participants with severe treatment-resistant depression. These participants averaged 8.1 prior antidepressant failures, and 63% were ECT-resistant.

Response reached 26.8%, remission 15.6%, and HDRS scores declined by 25.5%.

What Does This Research Suggest About Daily Low-Dose Ketamine Effectiveness?

The protocol that commercial providers actually market has not been studied in a prospective clinical trial. Daily low-dose oral racemic ketamine has not been shown to be effective for depression in published prospective research. It also has not been shown to be ineffective. The published evidence does not address the question.

How Does Other Ketamine Research Compare?

Conversely, a substantially larger body of research exists for periodic dosing schedules. Every prospective trial of oral or sublingual ketamine for depression that has reported response or remission used a periodic schedule, ranging from thrice-weekly to roughly weekly. Three of those studies are summarized below.

Sample sizes range from a 41-patient placebo-controlled RCT to a real-world effectiveness study of more than 11,000 patients. Response rates in these studies range from 26.8% to 56.4%. Direct comparisons across studies should account for differences in study design, patient populations, and outcome measures

The Mathai 2024 data represents a real-world effectiveness study of Mindbloom's at-home sublingual ketamine therapy program.⁷

What Is Known About the Safety of Daily or Frequent Ketamine Protocols?

The published safety data for ketamine in depression comes almost entirely from periodic therapeutic-dose protocols, which have been studied across thousands of patients in multiple peer-reviewed trials. That data does not extrapolate cleanly to daily sub-perceptual protocols, which use different dose ranges, different administration patterns, and a different patient experience.

Put plainly: this protocol has not been shown to be safe in any published prospective research. It also has not been shown to be unsafe. The peer-reviewed literature does not answer the question in either direction.

What Are Common Short-Term Side Effects?

Because no prospective trial has tested daily low-dose oral racemic ketamine for depression, the side effect profile of this specific commercial protocol has not been characterized in published research. The closest analog studies each used a different regimen on at least one dimension.

In Smith-Apeldoorn 2022, psychotomimetic effects were the most commonly reported side effects, with no serious adverse events recorded.¹ A separate 2013 study reported no psychotomimetic or dissociative effects at a very low 10 mg sublingual dose.⁸

The regimen commercially marketed as daily low-dose oral ketamine for depression has not had its side effect profile characterized in any prospective trial.

What Does the Published Evidence Show About Long-Term Daily Ketamine Use?

The longest prospective trial of daily oral (es)ketamine for depression lasted 21 days. No peer-reviewed prospective study has measured outcomes at 3 months, 6 months, 1 year, or longer for any daily oral ketamine protocol for depression.

Commercial daily-dosing protocols are marketed for ongoing or indefinite use, which is far longer than any published study has examined. Long-term use of this protocol has not been shown to be safe in published prospective research. It also has not been shown to be unsafe. The peer-reviewed literature does not address the question in either direction.

Who Should Not Use Ketamine Therapy?

Eligibility is a medical assessment process, not a set of binary rules. Not everyone is a good candidate for ketamine therapy — it may not be appropriate for individuals with uncontrolled hypertension, active psychotic disorders, active substance use disorders, pregnancy, and certain cardiac or respiratory conditions.

A licensed provider evaluates these factors during the screening process described above. Comprehensive medical screening before treatment is a core component of responsible ketamine therapy, not an optional step.

• Uncontrolled hypertension: Ketamine's sympathomimetic properties make cardiovascular screening essential.
• Active psychotic disorders: Ketamine's perceptual effects may not be appropriate.
• Active substance use disorders: Requires medical evaluation given ketamine's Schedule III classification.
• Pregnancy: Insufficient data on use during pregnancy.
• Certain cardiac or respiratory conditions: A specialist evaluates on a case-by-case basis.

Is Low-Dose Ketamine Addictive?

No prospective trial of daily low-dose oral racemic ketamine for depression has characterized abuse, dependence, or tolerance specifically in this protocol. In the broader published literature on supervised, sub-anesthetic ketamine use, abuse and dependence risk has generally been characterized as low.

Ketamine is classified as a Schedule III controlled substance by the DEA, indicating accepted medical use and a potential for abuse that may lead to moderate or low physical dependence or high psychological dependence. Documented dependence and tolerance are primarily from recreational contexts involving higher doses and unsupervised use.⁹

In supervised care settings, defined treatment durations and provider monitoring serve as safeguards. Whether the specific daily low-dose protocol carries distinct abuse or dependence risks has not been studied in peer-reviewed research. The protocol has not been shown to be non-addictive, and it has not been shown to be addictive. The question is unresolved in the peer-reviewed literature.

Conclusion

The published clinical evidence on daily low-dose oral ketamine for depression consists of one 21-day pilot in seven patients, using a different compound than commercial providers prescribe, with zero response and zero remission. The same research team used a less intensive schedule when they expanded their work to 185 patients. The protocol that commercial providers actually market has not been studied in any prospective trial.

The published evidence on periodic-dosing protocols is substantially larger. It includes a placebo-controlled randomized controlled trial, multiple open-label trials, and a real-world effectiveness study of more than 11,000 patients, with response rates between 26.8% and 56.4%.

The 21-day ceiling on daily-protocol research applies to every dimension of the question: effectiveness, safety, side effects, addiction risk, and long-term outcomes. Each of these is currently unanswered in the published literature for daily low-dose protocols specifically.

Anyone considering ketamine therapy should discuss the evidence and their individual circumstances with a licensed provider.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and may not be appropriate for patients with uncontrolled hypertension, active psychotic disorders, or certain substance use disorders; a licensed clinician should assess individual risk before treatment. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.